Xeris Biopharma Holdings Inc. Stock
A very strong showing by Xeris Biopharma Holdings Inc. today, with an increase of €0.40 (5.840%) compared to yesterday's price.
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 8 € there is a slightly positive potential of 10.1% for Xeris Biopharma Holdings Inc. compared to the current price of 7.27 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 5.840% | 2.367% | -0.602% | 17.005% | 15.059% | 249.327% | 265.309% |
| Heron Therapeutics Inc. | 5.840% | -31.089% | -20.320% | -73.274% | -73.178% | -79.946% | -96.948% |
| Evolus Inc | -0.060% | 35.230% | 25.286% | 50.500% | 32.550% | -18.831% | -21.049% |
| Rhythm Pharmaceuticals | 0.000% | 1.047% | 1.579% | 21.384% | 3.209% | 295.492% | 710.924% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat